KNOW YOUR RISKS. ACT NOW. STAY HEALTHY.
We build products that analyze routine biomarkers, multi-omics, and personal health data to detect long-term disease risks and guide prevention. Our first product, IduScore, will launch in April 2026.
Problem
Why don't we prevent them? Because Standard of Care detection occurs too late.
Most people find out after losing ~40% of kidney function, often irreversibly.1[1] National Kidney Foundation. Chronic kidney disease (CKD). Open source in new tab
4% death risk6[6] Death-risk source: Global Burden of Disease Study 2023 (Switzerland, adults aged 25 years and older). Values represent lifetime probability of death. Open source in new tab
For about 35% of people, the first presentation is a heart attack or an ischemic stroke.2[2] How Does Cardiovascular Disease First Present in Women and Men? PubMed 26330414. Open source in new tab
30% death risk6[6] Death-risk source: Global Burden of Disease Study 2023 (Switzerland, adults aged 25 years and older). Values represent lifetime probability of death. Open source in new tab
~50% of people are diagnosed once it has already metastasized.3[3] U.S. Cancer Statistics: Lung Cancer Stat Bite (CDC). Open source in new tab
5% death risk6[6] Death-risk source: Global Burden of Disease Study 2023 (Switzerland, adults aged 25 years and older). Values represent lifetime probability of death. Open source in new tab
~75% are never diagnosed4[4] World Alzheimer Report 2024. Open source in new tab, and among those who are, diagnosis is delayed by about 3.5 years after symptoms begin5[5] Diagnostic delay in dementia (PubMed 40716451). Open source in new tab.
10% death risk6[6] Death-risk source: Global Burden of Disease Study 2023 (Switzerland, adults aged 25 years and older). Values represent lifetime probability of death. Open source in new tab
Solution
Products
Based on each user's blood biomarkers and health data, we estimate how wellbeing is likely to evolve over the next 10 years and how likely the person is to experience poor wellbeing across multiple areas.
Current focus
Pipeline
We list which markers are driving each person's wellbeing score and in which direction. Even markers within the reference range can contribute negatively for a specific person. Identifying the top positive and negative contributors helps explain the score and personalize the actions most likely to improve it.
No two people receive the same recommendations. Actions are based on each person's scores and markers. Actions are ranked by expected impact and organized into achievable steps with a clear timeline.
Based on each user's blood multi-omic markers and health data, we use our proprietary models to estimate 10-year risk across multiple chronic and preventable diseases.
Current focus
Pipeline
Each disease risk score is paired with medically interpretable contribution analysis so clinicians and partners can understand what is driving or reducing risk. This makes risk calculations more explainable and supports better preventive decisions.
No two people receive the same preventive recommendations. Actions are based on each person's disease risk outputs and marker contributions, then prioritized by expected impact and organized into achievable clinical and lifestyle steps.
We calculate personalized optimal ranges for each biomarker by looking beyond one-size-fits-all population intervals. Our models consider how markers interact within each individual profile, because a value that is normal in the population may still be suboptimal for a specific person.
We use our proprietary models to adjust target ranges using biomarker interactions, age, sex, lifestyle, clinical history, and longitudinal context. This creates person-specific corridors that reflect biology more precisely than fixed population cutoffs.
Personalized target corridors make tracking actionable. They show whether each marker is moving toward its optimal range over time, so progress can be monitored, recommendations are prioritized, and plans are updated as biology changes.
Evidence and Governance
Up to 10 years
Detection before diagnosis
For 4 chronic diseases: Cardiovascular Disease (CVD), Chronic Kidney Disease (CKD), Dementia, and Lung Cancer.
We developed and validated our models using UK Biobank longitudinal data from about 500k participants followed for up to 15 years with linked medical records.
Because outcomes are observed (ground truth diagnoses), model performance can be evaluated directly against real disease events.
2x to 4x
Better Sensitivity (TPR)
Versus Standard of Care at 98% Specificity (TNR).
We benchmarked IduRisk against methods used in current clinical practice:
CSEM spin-off
Technology foundation
Idunox is a CSEM spin-off startup.
CSEM is a public-private, non-profit Swiss technology innovation center founded in 1984, with over 650 people across Switzerland and seven sites nationwide.
CSEM has collaborated with thousands of companies and helped create more than 50 start-up businesses and spin-offs. Among the most recognized are Hilo by Aktiia, Ava, Biospectal, Visienco, 3Brain, and Solaxess; spanning digital health, medtech, neurotechnology, and clean energy.
50 users tested
Strong validation ahead of launch
Our MVP has already been tested by 50 users from a waitlist of more than 300 people, confirming strong early demand and helping refine the user experience.
We will launch IduScore in Switzerland in April 2026 through our first at-home testing partner.
Cybersecurity
Infrastructure and operations
The ingestion and reporting stack applies layered controls: HTTPS/TLS transport, AES-256-GCM encryption at rest, strict CORS allowlists, and IP-based login/auth rate limits.
Operational safeguards include fail-fast secret checks, immutable audit trails, and production security validations (access control, headers, host hardening, and artifact protection).
Data Privacy
Governance and compliance
Privacy controls include pseudonymous subject-ID separation, data minimization, role-based access boundaries, retention/deletion policy governance, and processor oversight.
Program design follows GDPR principles and Swiss nFADP/FDPIC requirements for sensitive health-data processing.
Cases
Individuals (D2C)
Use IduScore to understand your long-term wellbeing and take actions to improve it.
Clinics, Labs, Insurers & Employers
Use our preventive products to support the health of your customers and employees.
Pharma and Biotech
Use longitudinal multi-omics and risk modeling to support discovery and clinical development.
Partners and Support
Team
Co-Founder and CEO
Serial founder with 15+ years across health, consumer, and technology businesses, leading product strategy and partnerships.
Co-Founder and CSO
Biomedical data scientist (PhD) focused on biomarkers, multi-omics, and translational science for chronic disease prevention.
Advisor
Head of Biometrics at Pierre Fabre, former AstraZeneca and Enterome, advising on biomarker strategy and clinical statistics.
Frequently Asked Questions (FAQ)
IduScore is a wellbeing and wellness product that estimates 10-year wellbeing trajectories, explains marker contributions, and prioritizes lifestyle actions. IduRisk estimates 10-year risk across chronic and preventable diseases, explains risk-driving marker contributions, and supports preventive follow-up planning. IduRange calculates personalized biomarker target corridors that go beyond one-size-fits-all population reference intervals.
IduScore is designed for wellbeing and wellness users who want personalized lifestyle guidance based on their biomarkers and health data.
IduRisk and IduRange are being developed for healthcare and partner settings where medically relevant information can support prevention, follow-up, and care decisions.
Depending on the product, inputs can include blood biomarker data, multi-omic measurements, health information, and relevant lifestyle or clinical context. The exact input set depends on the use case, product configuration, and deployment setting.
A practical update cadence is every 6 to 12 months. That is typically the time it takes for a user to establish new habits and begin seeing measurable effects in their molecular markers.
It means each person can receive a tailored target corridor for key biomarkers rather than relying only on broad population reference intervals. These ranges are adjusted using biomarker interactions, age, sex, lifestyle, clinical history, and longitudinal context to reflect the individual more precisely.
Recommended actions are generated by integrating each user's results with their current lifestyle and situation, then matching those inputs to clinically validated actions that have demonstrated impact in the relevant domains. Recommended actions are personalized to the individual rather than generated from generic rules alone.
Each recommended action is linked to a supporting source so users and partners can see the evidence behind the action.
Current focus diseases are Dementia, Lung Cancer, Cardiovascular Disease, and Chronic Kidney Disease, with a broader pipeline in active development including Bladder Cancer, Breast Cancer, Colorectal Cancer, Diabetes, Kidney Cancer, Obesity, Parkinson's, Prostate Cancer, and Skin Cancer.
IduScore is a wellbeing and wellness tool. It is designed to support lifestyle-related insights and actions only, does not address medical topics, and does not diagnose any disease.
IduRisk and IduRange also do not diagnose any disease, but they are intended to provide medically relevant information that can help guide medical care. Both are currently in development and are expected to be medical devices requiring the appropriate regulatory approvals before clinical use.
We do not sell user data. For product improvement, we only use fully anonymized data and keep it under strong safeguards within the company, including strict access controls, encryption, and controlled handling processes.
Users can request deletion of their data at any time, with no questions asked.
Yes. We are actively discussing partner integrations and preventive health workflows with clinics, labs, insurers, and other healthcare organizations, including environments that require stronger governance and operational controls.
Contact
Email: info@idunox.com
Idunox (not yet incorporated)
c/o CSEM Hegenheimermattweg 167A
4123 Allschwil
Switzerland
